OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

MOLECULAR PARTNERS N/  CH0256379097  /

SIX Swiss Exchange
6/2/2023  4:22:28 PM Chg. +0.380 Volume Bid4:33:34 PM Ask4:33:34 PM Market Capitalization Dividend Y. P/E Ratio
5.890CHF +6.90% 25,413
Turnover: 143,701.065		 5.900Bid Size: 619 6.000Ask Size: 7,582 212.66 mill.CHF - 1.63
GlobeNewswire 3/24/2022 Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 ...
GlobeNewswire 3/17/2022 Molecular Partners Publishes Invitation to Annual General Meeting 2022
GlobeNewswire 3/15/2022 Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
GlobeNewswire 2/25/2022 Molecular Partners to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire 2/11/2022 Molecular Partners to Present at Upcoming Healthcare Investor Conference
GlobeNewswire 2/10/2022 Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration f...
GlobeNewswire 1/18/2022 Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19
GlobeNewswire 1/13/2022 Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations
TeleTrader 1/10/2022 Novartis drug 78% efficient against COVID - trial
GlobeNewswire 1/10/2022 Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP042...
GlobeNewswire 1/5/2022 Molecular Partners to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire 12/15/2021 Molecular Partners to Host Oncology Day (Virtual)
GlobeNewswire 12/14/2021 Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Th...
GlobeNewswire 12/12/2021 Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Pre...
GlobeNewswire 12/9/2021 Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in December
GlobeNewswire 12/6/2021 Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ES...
GlobeNewswire 12/3/2021 Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Mul...
GlobeNewswire 11/30/2021 Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omic...
GlobeNewswire 11/24/2021 Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference
GlobeNewswire 11/16/2021 Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospi...
GlobeNewswire 11/4/2021 Molecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 C...
GlobeNewswire 10/28/2021 Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program...
GlobeNewswire 10/20/2021 Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with E...
GlobeNewswire 9/3/2021 Molecular Partners to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire 8/26/2021 Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021